Comparison of three immobilisation systems for radiation therapy in head and neck cancer

Parkin DM , Bray F , Ferlay J , Pisani P . Estimating the world [1] cancer burden: Globoscan 2000 . Int J Cancer 2001 ; 94 : 153 – 6 . Llovet JM , Ricci S , Mazzaferro V , Hilgard P , Gane E , [2] Blanc JF , et al. : Sorafenib in advanced hepatocellular carcinoma . N Eng J Med 2008 ; 359 : 378 – 90 . Cheng AL , Kang YK , Chen Z , Tsao CJ , Qin S , Kim JS , et al . [3] Effi cacy and safety of sorafenib in patients in the Asia-Pacifi c region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial . Lancet Oncol 2009 ; 10 : 25 – 34 . Lenciono R , Llovet JM . Modifi ed RECIST (mRECIST) [4] assessment for hepatocellular carcinoma . Semin Liver Dis 2010 ; 30 : 52 – 60 . Curtit E , Thiery-Vuillemin A , Nguyen T , Heyd B , Pivot X , [5] Di Martino V , et al . Complete histologic response induced by sorafenib in advanced hepatocellular carcinoma: A case report . J Clin Oncol 2011 ; 29 : e330 – 2 . Irtan S , Chopin-Laly X , Ronot M , Faivre S , Paradis V , [6] Belghiti J . Complete regression induced by sorafenib of locally advanced HCC allowing curative resection . Liver Int 2011 ; 31 : 740 – 3 . Yeganeh M , Finn RS , Saab S . Apparent remission of a [7] solitary metastatic pulmonary lesion in a liver transplant recipient treated with sorafenib . Am J Transplant 2009 ; 9 : 2851 – 4 . Kudo M , Ueshima K . Positioning of a molecular-targeted [8] agent, sorafenib, in the treatment algorithm for hepatocellular carcinoma and implication of many complete remission cases in Japan . Oncology 2010 ; 78(Suppl 1) : 154 – 66 . Chelis L , Ntinos N , Souftas V , Deftereos S , Xenidis N , [9] Chamalidou E , et al . Complete response after sorafenib therapy for hepatocellular carcinoma in an HIV-HBV co infected patient: Possible synergy with HAART? A case report. Med Oncol 2011 ; 28(Suppl 1) : S165 – 8 . Sacco R , Bargellini I , Gianluigi G , Bertini M , Bozzi E , [10] Altomare E , et al . Complete response for advanced liver cancer during sorafenib therapy: Case report . BMC Gastroenterol 2011 ; 11 : 4 . Abbadessa G , Rimassa L , Pressiani T , Carrillo-Infante C , [11] Cucchi E , Santoro A . Optimized management of advanced hepatocellular carcinoma: Four long-lasting responses to sorafenib . World J Gastroenterol 2011 ; 17 : 2450 – 3 . So BJ , Bekaii-Saab T , Bloomston MA , Patel T . Complete [12] clinical response of metastatic hepatocellular carcinoma to sorafenib in a patient with hemochromatosis: A case report . J Hematol Oncol 2008 ; 1 : 18 . Wang SX , Byrnes A , Verma S , Pancoast JR , Rixe O . Complete [13] remission of unresectable hepatocellular carcinoma treated with reduced dose of sorafenib: A case report . Target Oncol 2010 ; 5 : 59 – 63 . Inuzuka T , Nishikawa H , Sekikawa A , Takeda H , Henmi S , [14] Sakamoto A , et al . Complete response of advanced hepatocellular carcinoma with multiple lung metastases treated with sorafenib: A case report . Oncology 2011 ; 81(Suppl 1) : 152 – 7 .